Related Experiment Video

Updated: Aug 21, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

COX-2 inhibition as a tool to treat and prevent colorectal cancer

J B Tuynman1, M P Peppelenbosch, D J Richel

  • 1Department of Medical Oncology, Academic Medical Center, F4-223, Meibergdreef 9, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands.

Critical Reviews in Oncology/Hematology
|October 27, 2004
PubMed

Insights

Non-steroidal anti-inflammatory drugs (NSAIDs) show promise in preventing colorectal cancer by targeting cyclooxygenase-2 (COX-2) and other pathways. Further clinical trials are needed to confirm their efficacy as adjuvant therapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cyclooxygenase-2 (COX-2) plays a key role in colorectal cancer development.
  • The precise anticarcinogenic mechanisms of NSAIDs are not fully understood and are concentration-dependent.
  • NSAIDs exhibit both COX-2 dependent and independent effects against cancer.

Purpose of the Study:

  • To review the role of COX-2 in colorectal cancer (CRC) carcinogenesis.
  • To discuss the multifaceted anticarcinogenic mechanisms of NSAIDs.
  • To highlight the potential of NSAIDs as adjuvant therapy in CRC.

Main Methods:

  • Literature review summarizing data on COX-2 in CRC.
  • Analysis of NSAID mechanisms at different concentrations.
  • Examination of preclinical and clinical evidence for NSAID efficacy.

Main Results:

  • NSAIDs downregulate COX-2 gene expression at low concentrations.
  • At clinical concentrations, NSAIDs inhibit prostaglandin E2 production, reducing tumor angiogenesis.
  • Higher NSAID concentrations induce apoptosis and inhibit metastasis, angiogenesis, and proliferation in animal models.
  • NSAIDs and selective COX-2 inhibitors can prevent colorectal adenoma development.

Conclusions:

  • NSAIDs possess multiple anticarcinogenic targets beyond COX-2 inhibition.
  • The clinical application of NSAIDs as adjuvant CRC therapy is limited by a lack of long-term randomized trials.
  • Further research is required to translate preclinical findings into effective clinical strategies for CRC prevention and treatment.

More Related Videos

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine06:24

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Published on: October 13, 2023

A Co-culture Method to Investigate the Crosstalk Between X-ray Irradiated Caco-2 Cells and PBMC11:40

A Co-culture Method to Investigate the Crosstalk Between X-ray Irradiated Caco-2 Cells and PBMC

Published on: January 30, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...